At the interface between biology, pathophysiology, pharmacology and toxicology, safety pharmacology is a full-fledged discipline. It is also a key issue for all drug developers of the healthcare industry: unacceptable safety remains the most important reason for failure in preclinical and phase I studies (safety is also responsible for 30% of the phase II trial failures).
Over the past 40 years, ERBC has become a leader in the field, conducting annually more than 200 non GLP or GLP-compliant safety studies.
In partnership with world-class scientists of academia and industry, ERBC is also fully committed to the development of safety biomarkers and advanced methodologies that allow industrials to better predict the risk of rare lethal events induced by new therapies and improve safety margin calculation, reducing the risk of subsequent failure in clinical.
